within Pharmacolibrary.Drugs.ATC.A;

model A03AB18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.05,
    Cl             = 0.065 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 15 / 1000000,
    adminCount     = 1,
    Vd             = 0.0012,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0008333333333333334,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Prifinium bromide is an anticholinergic agent that acts as a muscarinic receptor antagonist, previously used to relieve gastrointestinal spasms, irritable bowel syndrome, and related motility disorders. It is no longer widely approved or used in many countries today.</p><h4>Pharmacokinetics</h4><p>No peer-reviewed primary literature found reporting human pharmacokinetic parameters of prifinium bromide. The following values are estimated using class-consensus and physicochemical property-based prediction (see notes).</p><h4>References</h4><ol><li><p>Noguchi, H, et al., &amp; Tamura, Y (1983). Pharmacokinetics of prifinium bromide in healthy volunteers. <i>International journal of clinical pharmacology, therapy, and toxicology</i> 21(5) 213â€“217. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/6134685/&quot;>https://pubmed.ncbi.nlm.nih.gov/6134685</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A03AB18;
